IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting
08. April 2022 16:15 ET
|
IO Biotech
Updated Data as of December 1, 2021 from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic MelanomaThree-year Survival Probability of 73%Subgroup analyses including patients...
IO Biotech Announces Year-End Results for 2021
31. März 2022 16:15 ET
|
IO Biotech
--Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma to be Presented at AACR in April-- -- Began Patient...
IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022
08. März 2022 16:30 ET
|
IO Biotech
Clinical Update from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic Melanoma from New Data Cut as of December 1, 2021 Multiple Subgroup Analyses Will be Presented for...
IO Biotech to Present at 42nd Annual Cowen Healthcare Conference
04. März 2022 08:00 ET
|
IO Biotech
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Appointment of David V. Smith to its Board of Directors
03. März 2022 16:05 ET
|
IO Biotech
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
09. Dezember 2021 11:05 ET
|
IO Biotech
NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel immune-modulating cancer therapies based on its T-win® technology,...
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial
06. Dezember 2021 08:00 ET
|
IO Biotech
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
09. November 2021 11:06 ET
|
IO Biotech
WILMINGTON, Del., Nov. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the closing of its initial public offering of 8,222,500 shares of its common stock,...
IO Biotech, Inc. Announces Pricing of Initial Public Offering
04. November 2021 23:52 ET
|
IO Biotech
WILMINGTON, Del., Nov. 04, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the pricing of its initial public offering of 7,150,000 shares of its common stock...